Postmarket surveillance under FDAMA should be last resort to other controls -- HIMA.
This article was originally published in The Gray Sheet
Executive Summary
POSTMARKET SURVEILLANCE SHOULD BE LAST RESORT IN FDA's "EARLY WARNING" SYSTEM, the Health Industry Manufacturers Association maintained at a Jan. 15 FDA/industry public meeting in Gaithersburg, Maryland on how to implement revisions to the agency's tracking and postmarket surveillance (PMS) programs mandated by the FDA Modernization Act (FDAMA).
You may also be interested in...
Postmarket Surveillance Plans May Be Less Burdensome Under Proposed Rule
Medical device manufacturers would be able to satisfy postmarket surveillance orders using secondary data collection methods or literature reviews, provided their proposed method answered the surveillance question posed by FDA, under an Aug. 29 proposed rule.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.